August 8, 2011 |
GlaxoSmithKline P.L.C. and Pfizer Inc. have sued generic drug giant Teva Pharmaceutical Industries Ltd. for allegedly infringing a U.S. patent for the HIV drug Epzicom, Bloomberg News reported. All three companies have large operations in the Philadelphia region. Glaxo and Pfizer have a joint venture, ViiV Healthcare, which makes Epzicom. Teva applied to the Food and Drug Administration to sell a generic version of Epzicom, ViiV lawyers said in a complaint filed in federal court in Wilmington, Del., Bloomberg said.
August 15, 2011 |
Men of a certain need must spend more money for more years after a federal judge sided with drugmaker Pfizer Inc. as it tried to fend off a generic version of its erectile dysfunction drug Viagra in a patent-protection lawsuit. The suit pitted two of the world's biggest drugmakers - Pfizer and Teva Pharmaceutical Industries Ltd. - both of which have local operations. Pfizer is the global leader in pharmaceutical sales and Teva leads the pack in generic drugs, which now account for about 75 percent of the market.
July 21, 2009 |
It took just a few minutes for the vast majority of Wyeth shareholders to say goodbye to the 83-year-old pharmaceutical giant at the company's last annual meeting yesterday. About 98 percent of Wyeth shareholders voted to approve the company's $68 billion acquisition by New York-based Pfizer. Wyeth is based in Madison, N.J., but employs about 5,000 people at operations in Collegeville and Malvern. The deal will solidify Pfizer's position as the top-selling drugmaker in the world and help it compensate for billions of dollars in revenue it likely will lose when its cholesterol fighter Lipitor loses its patent in 2011.
July 7, 2011 |
NEW YORK - Pfizer Inc. said Thursday it may sell its animal health and nutrition business in the next two years so it can focus on expanding its low-cost pharmaceuticals unit. Pfizer, which has faced pressure to eliminate some business units and return more cash to shareholders, said the moves will allow investors to get more value for the businesses. The company will also consider transactions including spinoffs and may pursue different strategies for each business. Any transactions could take one to two years to complete, Pfizer said.
October 15, 2009 |
Pfizer Inc. and Wyeth plan to close their $68 billion merger today, leaving employees at the companies' two Philadelphia-area sites wondering whether they'll be among the 20,000 to be laid off. The two companies employ about 130,000 people and have said that there will be layoffs. U.S. and Canadian antitrust regulators cleared the merger yesterday. Wyeth, based in Madison, N.J., employs about 4,500 people in this area - about 3,600 in Collegeville and 900 in Great Valley and other sites.
December 11, 2012
Nuron Biotech Inc., a specialty biologies and vaccines company based in Exton, said it acquired from Pfizer Inc., the vaccine Meningitec, used for the prevention of a potentially deadly infection caused by Neisseria meningitidis serogroup C. There are an estimated 500,000 cases of the infection annually worldwide, according to Nuron Biotech, but the U.S. Centers for Disease Control and Prevention estimated the rate of infection in the U.S. is...
July 13, 2013 |
Almost every organization of any size says innovation is important, but many struggle to apply new ideas successfully. Pfizer is the world's top seller of prescription medicine, and some of its 85,000 employees work in Collegeville, Montgomery County. Its vice president for worldwide innovation, Wendy Mayer, spoke Wednesday as part of panel during MedCityNews' two-day "Converge: Summit for Healthcare Innovation" at the Hyatt at the Bellevue. Mayer's five-person panel addressed the question: "How Can You Innovate in a Big Shop?"
December 21, 2012 |
The landscape for pharmaceutical employees has shifted again as Pfizer reportedly will lay off about 600 sales representatives in its primary-care division, according to Bloomberg News. Pfizer, based in Manhattan, has a large facility in Collegeville that is part of the company's specialty-care division and is apparently not affected by this decision. A Pfizer spokesman declined to confirm the number reported by Bloomberg but said in a statement: "As part of our strategy to allocate our resources, investments, and people to the areas that best serve our patients and customers, we continually evaluate how we can be more efficient and effective.
January 31, 2013 |
Pfizer Inc. chief executive officer Ian Read said Tuesday that the world's largest seller of pharmaceutical products will keep examining whether to one day separate the management of its "innovative" drugs from "established" drugs, with patents that have expired. Since digesting the $69 billion acquisition of Wyeth in 2009, Pfizer has been trying to get the most it can from its business operations while negating the loss of revenue from blockbuster drugs such as Lipitor, which now has generic competition.